Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Access Restricted, Aduhelm Appears Poised For A Slow Start

Payers Speak Out At ICER Public Meeting

Executive Summary

Reimbursement, health policy and medical experts predicted a slow rollout ahead for Biogen's new Alzheimer's treatment at a public meeting sponsored by ICER.

You may also be interested in...



Podcast: What's Ahead For Aduhelm's Launch And Reimbursement

Scrip and Pink Sheet editors join Datamonitor Healthcare analysts to discuss Biogen's Aduhelm for Alzheimer's disease, including the expected launch trajectory, early commercial barriers to uptake and the Medicare reimbursement environment.

Biogen Fires Back At Critics In Defense Of Aduhelm

Management tried to sidestep controversy around the approval of Aduhelm and said it remains confident the drug will be reimbursed.

Aduhelm Invades Senate Committee’s COVID-19 Hearing

Woodcock again defends the decision, saying Congress intended accelerated approval for those situations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel